Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Combination Therapy With Oseltamivir and Zanamivir Versus Monotherapy in the Treatment of Virologically Confirmed Influenza in Primary Care a Randomised Double Blind Controlled Trial Study.

Next Previous
X
Search
Trial Profile

Evaluation of Combination Therapy With Oseltamivir and Zanamivir Versus Monotherapy in the Treatment of Virologically Confirmed Influenza in Primary Care a Randomised Double Blind Controlled Trial Study.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oseltamivir (Primary) ; Zanamivir (Primary)
  • Indications Influenza A virus infections
  • Focus Therapeutic Use
  • Acronyms BIVIR

    • Most Recent Events

    • 01 Jan 2011 Results published in PLoS Medicine.
    • 30 Dec 2010 Planned end date changed from 1 May 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 30 Dec 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top